Cartesian Therapeutics, Inc. (RNAC)

Market Cap	197.87M -15.4%
Revenue (ttm)	1.48M +44.0%
Net Income	-151.89M
EPS	-5.61
Shares Out	30.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,744
Open	6.26
Previous Close	6.28
Day's Range	6.13 - 6.53
52-Week Range	5.60 - 11.00
Beta	0.72
Analysts	Strong Buy
Price Target	33.67 (+414.83%)
Est. Earnings	Nov 9, 2026

About RNAC

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyosi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 22, 2016
• Employees: 75
• Stock Exchange: Nasdaq
• Ticker Symbol: RNAC
• Website: https://www.cartesiantherapeutics.com

Financial Performance

In 2025, Cartesian Therapeutics's revenue was $2.80 million, a decrease of -92.81% compared to the previous year's $38.91 million. Losses were -$130.30 million, 68.3% more than in 2024.

Analyst Summary

According to 7 analysts, the average rating for RNAC stock is "Strong Buy." The 12-month stock price target is $33.67, which is an increase of 414.83% from the latest price.

Price Target

$33.67

(414.83% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 27, 2026

Data Sources Report a data error